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E-mail address: rklein@dom.wustl.edu (R.S. Klein)Myelin, a dielectric sheath that wraps large axons in the central and peripheral nervous systems, is
essential for proper conductance of axon potentials. In multiple sclerosis (MS), autoimmune-medi-
ated damage to myelin within the central nervous system (CNS) leads to progressive disability pri-
marily due to limited endogenous repair of demyelination with associated axonal pathology. While
treatments are available to limit demyelination, no treatments are available to promote myelin
repair. Studies examining the molecular mechanisms that promote remyelination are therefore
essential for identifying therapeutic targets to promote myelin repair and thereby limit disability
in MS. Here, we present our current understanding of the critical extracellular and intracellular
pathways that regulate the remyelinating capabilities of oligodendrocyte precursor cells (OPCs)
within the adult CNS.
 2011 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Multiple sclerosis (MS) is characterized by progressive clinical
decline due to axonal loss from chronic demyelination [1].
Although for many patients early disease is characterized by
remyelination and recovery of function, eventually remyelination
becomes limited and ultimately fails, for unclear reasons, leading
to worsening disability [2]. Indeed, acutely injured axons may be
found within demyelinated and actively demyelinating lesions,
suggesting an intimate association between the mechanisms lead-
ing to myelin and axonal injury [3]. As oligodendrocyte precursor
cells (OPCs) can be detected in MS lesions, it would seem that
the endogenous repair mechanisms that normally respond to mye-
lin damage become defective throughout the course of disease.
Thus, there is great interest in understanding these mechanismschemical Societies. Published by E
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.in order to identify reasons for failure and to develop therapies that
promote the proliferation, migration and/or differentiation of OPCs
in areas where demyelinated axons are at risk for further damage.
Animal studies examining remyelination utilize a variety of ap-
proaches, which each highlight essential aspects of OPC biology.
Thus, in murine models white matter damage is caused by induc-
tion of myelin-reactive immune cells via immunization or infection
with mouse hepatitis virus (MHV), the latter of which leads to an
acute encephalitis followed by a chronic demyelinating phase
due to viral persistence within oligodendrocytes, or via use of
ingestible or injectable toxins, such as cuprizone or lysolecthin,
respectively, which induce apoptosis speciﬁcally in oligodendro-
cytes [4,5]. Findings in these models have been difﬁcult to validate
in MS patients primarily because human studies of demyelinated
lesions are generally limited to analyses of postmortem tissue in
patients with longstanding, progressive disease [2]. Many of these
samples do not exhibit the dynamic OPC behaviors observed in
animal models due to the physical and chemical barrier presented
by astrogliosis. In this review, we will brieﬂy outline the molecular
pathways involved in regulation of remyelination that have been
identiﬁed using animal experimentation and, where data are avail-
able, in validative studies performed using human tissues. The
studies published so far provide hope that as critical myelin repair
mechanisms are unraveled in the adult brain, there will be demon-
strable targets for the correction of these processes in MS.lsevier B.V. All rights reserved.
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Remyelination is the regeneration of an axon’s myelin sheath
that has been damaged in many diseases such as MS. In general,
the cellular mechanisms that mediate remyelination are a recapit-
ulation of processes that occur during development. However, cer-
tain extracellular signaling molecules, such as chemokines, appear
to function similarly during developmental myelination and
remyelination. In the postnatal and adult brain, oligodendrocyte
lineage cells migrate from the subventricular zone (SVZ) to the
developing white matter where they stop proliferating, differenti-
ate and myelinate axons [6–8]. Similar events have been shown to
occur during remyelinating phases in mouse models of demyelin-
ation [5,9–11]. For example, in both the lysolecithin-induced focal
demyelination model, where toxin in directly injected into white
matter areas, and in the cuprizone intoxication model, in which
ingestion of copper chelator leads to complete demyelination of
the corpus callosum, chondroitin sulphate proteoglycan positive
(NG2+) cells are recruited to areas of demyelination from the sub-
ventricular zone (SVZ) [5,12,13]. These cells differentiate and be-
come oligodendrocytes that express myelin proteins in a
sequential manner such that proteolipid protein (PLP), myelin ba-
sic protein (MBP) and 20,30-cyclic nucleotide 30-phosphodiesterase
(CNPase) are expressed within ﬁve days of toxin cessation, whereas
myelin oligodendrocyte glycoprotein (MOG) is not expressed until
8 weeks after the initiation of remyelination [5,9,14]. Thus, the
mechanisms that mediate remyelination are tightly regulated,Fig. 1. Putative remyelination mechanisms. Depicted are roles for cytokines, chemokines
of demyelinated lesions in MS. During demyelination, oligodendrocytes undergo apo
astrocytes, which then express cytokines (TNF-a, IL-1b) [15–16]. Cytokines alter expres
EGF), whose activation or inhibition of various aspects of remyelination are depicted via
(migration, proliferation, OPC survival and differentiation). For certain molecules, such a
model used. Growth factors differentially impact on cell survival and proliferation while
TLR2 activation inhibits OPC differentiation [79]. Notch-1 also blocks OPC differentiation
context of intracellular signaling during differentiation. Included are chemokine (CXCR4/
transcription factors (Nkx2.2, Olig1/2, Mash1, Tcf4, SOX10) which may negatively or po
(PLP), myelin basic protein (MBP) and myelin oligodendrocyte glycoprotein (MOG).orchestrating a speciﬁc sequence of events (Fig. 1). A variety of
proteins have been found to impact on remyelination including
cytokines [15,16], chemokines [9,11,17–20], signaling molecules,
[21–24], growth factors [5,12,25], transcription factors [26–28]
and microRNA [29–32]. However, the speciﬁc role of each of these
proteins during remyelination is unknown and simply inhibiting or
augmenting expression of any one of these molecules may not be
sufﬁcient to promote remyelination in humans. Instead a compre-
hensive understanding of the functions of these molecules is nec-
essary to devise effective treatment strategies for remyelination
failure in MS.3. Cytokines
Cytokines mediate inﬂammatory responses that promote path-
ogen clearance and prevent excessive tissue damage [33]. How-
ever, overproduction of cytokines may lead to excessive
inﬂammation and cell death, as has been observed in peripheral
autoimmune diseases such as rheumatoid arthritis, psoriasis and
inﬂammatory bowel disease [34–36]. While successful targeting
of cytokine production has led to effective treatments for some
of these conditions [34–36], in the CNS certain cytokines exhibit
critical roles in repair mechanisms. Thus, understanding down-
stream effects of cytokine signaling pathways in the CNS is essen-
tial for creating MS treatments that both prevent damage and
promote repair., growth factors, transcription factors and other signaling proteins in remyelination
potosis, leaving debris, which may contribute to the activation of microglia and
sion of chemokines (CXCL1, CXCL2, CXCL12) and growth factors (IGF-1, PDGF, FGF,
color-coding of arrows and signs of blockade, respectively, for each biologic process
s CXCL1/2, opposing effects on OPCs have been observed, depending on the animal
chemokines contribute to migration and differentiation, depending on OPC position.
to promote migration. Molecules that regulate OPC maturation are depicted in the
7, CXCR2) and growth factor (IGF-1R, EGFR) receptors, miRNAs, Lingo-1 and several
sitively impact on the expression of myelin proteins including proteolipid protein
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nals through TNFR1 and TNFR2, activates two different pathways:
one that leads to apoptosis via death domain mediated caspase
activation (TNFR1) and another that activates survival and protec-
tive pathways via nuclear factor kappa B (NFjB) (TNFR1 and
TNFR2) [37,38]. As TNFR1 binds the soluble form of TNF-a while
TNFR2 binds the membrane bound form, the downstream effects
of TNF-a signaling depend on the proximity of cellular sources of
both ligand and receptor. Compared to unaffected individuals,
MS patients exhibit high levels of TNF-a in both the cerebrospinal
ﬂuid and serum, which are positively correlated to severity of le-
sions [39–41]. In mice with experimental autoimmune encephali-
tis (EAE) induced by immunization with myelin peptides,
overexpression of TNF-a worsens demyelinating disease and
administration of anti-TNF-a neutralizing antibodies or receptor
fusion proteins is protective [42–47]. Despite these ﬁndings, clini-
cal trials with, lenercept, a TNFR1 receptor extracellular domain
fused to human IgG1 heavy chain, resulted in increased frequency,
duration, and severity of MS exacerbations [48], suggesting alter-
native roles for TNF-a and/or its receptors that may depend on
the disease stage. Studies using mice with targeted deletions of
TNF-a or its receptors demonstrate that TNF-a mediates remyeli-
nation via TNFR2 signaling. Administration of cuprizone to TNF-a
and TNFR2 knockout mice led to a signiﬁcant delay in remyelina-
tion compared with wildtype control mice [15]. The attenuation
in remyelination correlated with a reduction in the pool of prolif-
erating oligodendrocyte progenitors and reduced mature oligoden-
drocytes. Analysis of mice lacking TNFR1 or TNFR2 indicated that
TNFR2 is necessary for oligodendrocyte maturation [35]. These
data suggests that TNF-a plays a role in CNS repair of myelin and
explain the failure of anti-TNF agents to alleviate disease in MS
patients.
Interleukin (IL)-1b is a proinﬂammatory cytokine associated
with the pathology of demyelinating disorders such as MS and viral
infections of the CNS and is induced during demyelination in ani-
mal models [16,49,50]. Although IL-1b exerts cytotoxic effects on
mature oligodendrocytes in vitro [51,52], IL-1b knockout mice do
not exhibit differences in the severity of demyelination, the deple-
tion of mature oligodendrocytes or the accumulation of oligoden-
drocyte progenitors within demyelinating lesions compared to
wild-type mice during cuprizone-induced demyelination [16].
However, IL-1b knockout mice fail to adequately remyelinate due
to lack of IL-1b–mediated expression of insulin growth factor
(IGF)-1 [16,53]. The expression of IGF-1 message and protein paral-
lels the accumulation and differentiation of oligodendrocyte pro-
genitors within the lesion, which the IL-1b knockout mice do not
exhibit [16,53]. Similar to TNFa, IL-1b has been associated with
exacerbating CNS pathology [49,54]. Conversely, it aids in repair
by inducing growth factor production to promote mature oligoden-
drocyte differentiation and remyelination during a pathological in-
sult within the CNS4. Chemokines and MS
Chemokines induce directed chemotaxis in nearby responsive
cells, which is necessary to guide immune cells to sites of infec-
tion or injury. Many chemokines including CXCL12 and CXCL1
are induced during CNS development and direct the migration
and maturation of neural precursor cells [55–57], suggesting
that these molecules could mediate migration and differentia-
tion during repair of CNS. Because remyelination failure may
be due to either the lack of differentiating signals or the pres-
ence of inhibitory signals for OPCs, chemokine neurobiology
has become an important area of investigation in studies of
remyelination.CXCL12 (formerly called stromal cell-derived factor (SDF)-1) is a
potent leukocyte chemoattractant that controls B-cell lymphopoi-
esis and hematopoietic stem cell homing to bone marrow via sig-
naling through G-protein-coupled receptor CXCR4 [58]. CXCR4
signaling is conserved in vertebrates, as it controls primordial germ
and sensory cell migration in zebraﬁsh [59]. Another CXCL12
receptor is the newly discovered receptor, CXCR7 that primarily
acts to regulate CXCR4 activation via sequestration of CXCL12
[60]. Although studies of CXCR7 in the developing brain are lim-
ited, there have been some reports that OPCs may express CXCR7
[61]. Freshly isolated neonatal OPCs speciﬁcally respond to CXCL12
by directed chemotaxis, however, their maturation into oligoden-
drocytes is associated with increased and decreased expression
of CXCR7 and CXCR4, respectively [61–63]. Indeed, studies using
in vivo demyelinating models support the notion that CXCR4 plays
an early role in the migration and differentiation of OPCs. In ele-
gant studies by Carbajal et al., (2010), GFP+ neural stem cells
(NSCs) introduced into the spinal cords of mice with chronic demy-
elination due to infection with MHV strain JHMV resulted in their
migration, proliferation, and differentiation into mature oligoden-
drocytes [11]. Administration of anti-CXCL12 neutralizing antibod-
ies or a small molecule inhibitor of CXCR4, but not CXCR7, resulted
in a marked attenuation in both the migration and proliferation of
the engrafted stem cells. Using the cuprizone model of remyelina-
tion, Patel et al., (2010) showed that CXCL12 speciﬁcally mediates
OPC differentiation into mature, myelinating oligodendrocytes
within the corpus callosum [9]. In these studies, antagonism of
CXCR4 via pharmalogical blockade or in vivo RNA silencing led to
arrest of OPC maturation, preventing expression of myelin proteins
[9]. Taken altogether, these data suggest roles for CXCL12 and
CXCR4 in the recruitment, proliferation and differentiation of OPCs
during remyelination of the adult CNS.
Studies of human CNS tissues indicate that CXCL12 is expressed
by endothelial cells and astrocytes (EC) within normal brain and is
increased in these and other cells in a variety of diseases including
neuroAIDS, stroke and MS [64–67]. Thus, analysis of active MS le-
sions, which exhibit some amount of remyelination, exhibit in-
creased CXCL12 expression in astrocytes throughout lesion areas
and in macrophages within vessels and perivascular cuffs, with
low levels of staining on ECs [66]. In chronic MS lesions, however,
less CXCL12 was observed with staining detected only within
hypertrophic astrocytes near the lesion edge, suggesting a mecha-
nism for loss of remyelination [64]. Because CXCL12 is required to
recruit CXCR4+ OPCs for remyelination, but also restricts the entry
of CXCR4+ immune cells at EC barriers [66,68], therapies that pro-
mote CXCL12 expression may target both effects of CXCL12 signal-
ing. Several studies suggest IL-1b and TNF-a may induce CXCL12
expression within endothelial cells and astrocytes [69,70] while
interferon (IFN-c) triggers decreased expression of the chemokine
[71]. IFN-c has also been shown to decrease EC expression of
CXCR7, which controls levels of abluminal CXCL12 [71]. Thus,
anti-cytokine biologicals are likely to impact on remyelination
via both direct effects on cytokine signaling and indirect effects
on patterns of chemokine expression.
4.1. CXCL1/CXCL2/CXCR2
CXCR2 plays a role in inﬂammation, oligodendroglial biology
and myelin disorders [72]. Studies in mouse models of remyelina-
tion and of MS lesions demonstrate roles for CXCR2 and its ligands
in both inﬂammation and repair. In active MS plaque lesions,
CXCR2 is expressed by proliferating oligodendrocytes and reactive
astrocytes, while its ligand, CXCL1, is expressed by activated astro-
cytes [20,73], suggesting CXCL1 expression in astrocytes may re-
cruit OPCs to the site of the lesion. However, other studies have
shown that CXCR2 activation limits migration of OPCs [57]. In
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lia at lesion borders, suggesting alternative functions for CXCR2 in
response to injury [74]. Thus, CXCL1/CXCR2 may be involved in
both the inﬂammatory component of MS and in OPC responses
during remyelination.
Results in rodent models provide further support for the dual
role of this chemokine and its receptor. Lui et al. (2010) detected
CXCR2 expression on neutrophils, oligodendrocyte progenitor cells
(OPCs), and oligodendrocytes in the CNS [18,19]. CXCR2-positive
neutrophils contribute to demyelination in EAE and during cupriz-
one intoxication [18,19] and systemic injection of a small molecule
inhibitor of CXCR2 at the onset of EAE decreased numbers of
demyelinated lesions [19]. Bone marrow chimeric mice generated
via transfer of CXCR2+/ bone marrow into non-lethally irradiated
CXCR2+/+ and CXCR2/mice led to more proﬁcient myelin repair
in CXCR2/ versus CXCR2+/+ recipients [19], suggesting that
CXCR2 signaling inhibits repair when expressed by radiation insen-
sitive neural cells. In vivo analysis showed that OPCs proliferated
earlier in the demyelinated lesions of CXCR2/ chimeric mice
and in greater numbers than in tissues from CXCR2+/+ chimeric
animals [18,19]. Demyelinated CNS slice cultures also demon-
strated enhanced myelin repair when CXCR2 was blocked with
either genetic deletion or neutralizing antibodies. These data sug-
gest that loss of CXCR2 activity both attenuates demyelination
and promotes OPC proliferation and differentiation. However, data
in other contexts question whether this receptor may be used as a
treatment target for demyelinating diseases.
CXCR2 signaling also protects oligodendrocytes and limits
demyelination in murine models of virally-induced demyelination
[17]. Demyelination induced by JHMV infection induced expres-
sion of the chemokines CXCL1 and CXCL2 and their receptor CXCR2
within the spinal cord during the chronic infection phase [17].
CXCR2 antagonism with neutralizing antiserum in this setting de-
layed clinical recovery and resulted in increased numbers of apop-
totic cells mainly within white matter tracts of the spinal cord [17].
Omari et al., (2009) also reported a protective role for CXCR2 dur-
ing demyelination [75]. In transgenic mice during EAE, overexpres-
sion of CXCL1 in astrocytes led to a decrease in clinical severity, a
decrease in demyelination and augmentation of remyelination
[75]. Lane and colleagues suggest that the protective and pro-
apoptotic roles of CXCR2 with regards to oligodendrocytes may
be context dependent [17]. Therefore, further studies are necessary
to fully determine the role of CXCR2 and its ligands during remye-
lination before therapeutic targets can be developed.5. Toll-like receptors
Toll-like receptors (TLRs) have well deﬁned roles in innate
immunity, but they also inﬂuence axonal pathﬁnding, dorsoventral
patterning and hippocampal neurogenesis [76,77]. Recently, TLR-2
and its ligand, hyaluronan was detected in MS lesions and in nor-
mal appearing white matter [78,79]. OPC differentiation has been
shown to be inhibited by several TLR2 agonists including hyaluro-
nan [79]. These data suggest that TLR signaling could inhibit
remyelination in MS and negatively impact on recovery during
exacerbation. The development of therapies that inhibit TLR could
therefore potentially alleviate failed remyelination in MS.
6. Growth factors
Growth factors are deﬁned as biologically active polypeptides
that control growth and differentiation of responsive cells. Several
of these growth factors were found to inﬂuence oligodendrocyte
biology both in vitro and in animal models of remyelination.
Growth factors have the potential to be a viable treatment optionfor MS. Transgenic mice overexpressing human epidermal growth
factor receptor (hEGFR) exhibit increased lesion repopulation by
OPCs with accelerated remyelination and functional recovery fol-
lowing focal demyelination of mouse corpus callosum compared
to wild-type mice [5]. EGFR overexpression in SVZ and corpus cal-
losum during early postnatal development also increased progeni-
tor populations and promoted SVZ-to-lesion migration, enhancing
oligodendrocyte generation and axonal myelination [5]. These data
suggest that EGFR signaling during remyelination is similar to its
role during development. EGF levels in the CSF of MS patients with
relapsing-remitting or secondary progressive forms were signiﬁ-
cantly lower than those of non-clinical controls [80], suggesting
that insufﬁcient levels of EGF is associated with remyelination fail-
ure. Targeting EGF to enhance remyelination may hold promise for
MS patients.
Several additional growth factors that are expressed during
demyelination and implicated in remyelination include insulin-
like growth factor (IGF)-1, platelet derived growth factor (PDGF),
and ﬁbroblast growth factor (FGF) [53,81]. IGF-1 has both a protec-
tive and mitogenic role during de/remyelination in the cuprizone
model. Thus, mice with targeted deletion of IGF-1 exhibit impair-
ments in OPC proliferation and survival and inadequate remyelina-
tion after cuprizone-induced demyelination [53,82,83]. In addition,
in transgenic mice engineered to continuously express IGF-1, oli-
godendrocytes are protected from apoptosis during cuprizone
intoxication [83]. Although a pilot study in which seven MS pa-
tients were given recombinant human IGF failed to show any sig-
niﬁcant differences, the drug was well tolerated [84]. Further
studies are ongoing to determine the efﬁcacy of IGF in promoting
repair in patients with MS. PDGF and FGF are well-established tro-
phic factors that promote the proliferation and differentiation of
NSCs. In mice infected with MHV-A59 to induce focal demyelina-
tion of the spinal cord, PDGF and FGF were identiﬁed as mitogens
regulating the proliferative responses of OPCs [81]. These studies
demonstrate that growth factors have impact on all aspects of oli-
godendrocyte biology and remyelination.7. Signaling pathways
Many factors have been identiﬁed that orchestrate the differen-
tiation and maturation of oligodendrocytes, but there are several
intracellular signaling pathways that possibly mediate remyelina-
tion including, Notch-1, LINGO-1 (leucine rich repeat and Ig do-
main containing NOGO receptor interacting protein 1) and Wnt.
Given the extensive recent reviews on Wnt signaling pathways
[85,86], it will not be discussed in this review.
LINGO-1 is a protein that is abundantly expressed in the cortex
of CNS and has been in implicated in the inhibition of axon regen-
eration [87]. It also regulates remyelination in the adult CNS by
inhibiting oligodendrocyte differentiation. This process is a reca-
pitulation of LINGO-1 function during developmental myelination
[88]. Using 3 different animal models of de/remyelination: EAE,
cuprizone induced demyelination, and lysophophatidylcholine
(LPC) induced demyelination, Mi et al., (2009) demonstrated that
LINGO-1 antagonism enhanced OPC differentiation and promoted
remyelination of demyelinated axons [88]. Furthermore, LINGO-1
antagonism using monoclonal antibody 1A7 in the EAE model
showed improvement in axonal integrity and the formation of
new myelin sheath [89]. These data suggest that LINGO-1 antago-
nism has potential as a therapy for CNS repair of demyelinating
disease. Recently, clinical trials have begun that will administer
LINGO-1 antagonist BIIB033 to MS patients to determine CNS re-
pair [90]. The efﬁcacy of drug will be assessed via neurological
examinations, MS performance scores, and brain magnetic reso-
nance imaging (MRI) scans.
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volved in gene regulation mechanisms including those that induce
neuronal development [21,91]. Non-myelinating oligodendrocytes
express Notch1 receptors, and neurons/axons express its ligand,
Jagged1 or contactin [22,92]. Binding of Jagged1 to Notch induces
expression of the transcription factor Hes5, which blocks the mat-
uration of Notch1-expressing cells, facilitating the migration of
OPCs to white-matter tracts of the CNS [92–94]. As development
proceeds, downregulation of Jagged1 is associated with the matu-
ration of oligodendrocyte precursors and myelination [94]. In ac-
tive MS lesions, Jagged1 was detected within reactive astrocytes,
whereas Notch1 and Hes5 were found within oligodendrocytes
[23]. In contrast, astrocytes in remyelinated areas did not show
Jagged1 expression. In addition, outgrowth of processes of human
oligodendrocyte cultures was blocked when cells were transfected
with Jagged1 [23,95]. These data suggest that notch-1 may inhibit
differentiation of OPCs in order to facilitate their migration to the
white matter.8. MicroRNA
MicroRNA are small RNA molecules that function as posttran-
scriptional regulators of gene function either through translational
inhibition or target RNA degradation [31]. These molecules have
recently emerged as mediators of many biological functions
including the proliferation and differentiation of NPCs [96] and
several groups have demonstrated that microRNAs exert roles in
remyelination. Junker et al., (2009) created microRNA proﬁles from
active and inactive MS lesions via laser capture microdissection of
single cells and showed dysregulation of transcripts such as CD47,
which is expressed by apoptotic cells to prevent macrophage
phagocytosis, speciﬁcally in active lesions [29]. The authors specu-
lated that loss of microRNA-mediated reduction of CD47 could
potentially release macrophages from inhibitory control, thereby
promoting phagocytosis of myelin. This mechanism may have
broad implications for miRNA-regulated macrophage activation
in inﬂammatory diseases [29].
Several studies demonstrate that oligodendrocyte maturation
may depend on microRNAs. Dugas et al (2010) showed that condi-
tional deletion of Dicer1, a miRNA-processing enzyme, prevented
OPC differentiation in vitro due to the lack of mature miRNAs. Fur-
thermore, microRNA microarray analysis has identiﬁed two
miRNAs, miRNA-219 and mi-338, necessary for oligodendrocyte
differentiation. Inhibition of these speciﬁc miRNAs prevents tran-
scription factor induction of OPC maturation [32]. The role of
miRNAs in remyelination, however, is unclear as studies have yet
to evaluate miRNAs in this context. Future studies will determine
whether these small molecules also regulate remyelination.
9. Transcription factors
Both myelination and remyelination occur through the activa-
tion of myelin protein genes that are induced by various transcrip-
tion factors. The sequential activation of myelin protein correlates
with both activation and inhibition of several transcription factors
such as Olig1, Olig2 and Nkx2.2. Olig1 is a basic helix–loop–helix
(bHLH) transcription factor expressed by oligodendrocytes in the
CNS [97]. This transcription factor is critical for developmental
myelination and Olig1/ mice have a shortened life span [98],
resulting from a failure to induce myelin speciﬁc gene expression
and arrested myelination. Recently, a critical role for Olig1 in
repairing demyelinated lesions in the adult CNS has been demon-
strated [97]. Olig1 translocates from the cytoplasm to the nucleus
in early remyelinating lesions in EAE as well as in oligodendrocyte
precursor cells at the edge of MS lesions [97]. Another transcriptionfactor known as SOX10 is part of the SOXE family of transcription
factors, which are known to regulate oligodendrocyte fate [99].
SOX10 plays a major role in the promoting terminal oligodendro-
cyte differentiation and loss of SOX10 activity leads to disruption
of oligodendrocyte differentiation [100]. Recent data has shown
that Olig1 and SOX10 can complex together to synergistically acti-
vate MBP gene transcription [101]. Several transcription factors,
such as Mash1 and Tcf4, have been used to identify cells within
the oligodendrocyte lineage but are additionally expressed by mul-
tipotent progenitor cells within neurogenic zones [102,103]. Tcf4
has also been demonstrated to function in catenin-dependent
Wnt signaling [104].
Olig2 and Nkx2.2 are transcription factors expressed by OPCs
and mature oligodendrocytes. Recent studies have revealed the
importance of Olig2 for the differentiation of neural progenitor
cells into the oligodendroglial lineage [27,105], while Nkx2.2 reg-
ulates the maturation and differentiation of oligodendroglial pro-
genitors [28]. Overexpression of Olig2 induces differentiation of
neural stem cells into mature oligodendrocytes in vitro [106]
and disruption of Olig2 in vivo leads to a lack of NG2+ OPCs
and decreased numbers of oligodendrocytes in the spinal cord
[27,107]. In contrast, loss of Nkx2.2 results in increased numbers
of OPCs [28]. Strong Olig2 or Nkx2.2 signals were observed in
OPCs in the spinal cord of adult mice, while mature oligodendro-
cytes expressed low levels of these two transcription factors sug-
gesting that a speciﬁc pattern of transcription factor coexpression
correlates with the stage of OPC/oligodendrocyte maturation [26].
As transcription factors and the myelin genes they induce are the
ﬁnal targets of many of the molecules discussed in this review, di-
rect targeting of myelin gene expression as a method to treat
remyelination failure in MS may prove to be the most powerful
approach.
10. Concluding remarks
Although studies demonstrate that the CNS is capable of
responding to myelin damage by triggering developmental mech-
anisms that induce remyelination, it is unclear why endogenous
repair mechanisms ultimately fail in patients with MS. Given that
OPCs and premyelinating oligodendrocytes may be detected in
acute MS lesions [108], it would seem that remyelination is likely
hindered by a block in differentiation pathways. Molecules that
interfere with remyelination may be derived from inﬁltrating im-
mune cells or activated glia, as discussed above [18,109]. Of inter-
est, chronically demyelinated lesions are frequently observed to
contain few OPCs and mostly activated astrocytes [108,110], sug-
gesting that astrogliosis prevents OPC differentiation or that OPCs
that fail to differentiate along the oligodendrocyte lineage induce
astrogliosis or, somehow, become astrocytes themselves [111]. It
is also possible that the repair mechanisms triggered by CNS dam-
age during MS not only contribute to chronic leukocyte inﬁltration
but also induce neuronal injury responses that prevent remyelina-
tion. Future studies will ultimately identify these context-speciﬁc
molecules that impact on neural precursor cell differentiation.
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